Behavioral Economics to Improve Flu Vaccination Using EHR Nudges Replication
BE IMMUNE Rep
BE IMMUNE: Behavioral Economics to IMprove and Motivate Vaccination Using Nudges Through the EHR, A Replication Trial
2 other identifiers
interventional
26,248
1 country
1
Brief Summary
This study will be a 6-month, cluster randomized, pragmatic replication trial to evaluate the effectiveness of personalized nudges to clinicians and patients, relative to a control, to increase flu vaccination rates among older adults in accordance with CDC guidelines. This will include clinician and patient level nudge interventions, with additional, intensified nudge interventions for patients identified as high risk for not receiving a flu vaccine. Among the intervention clinics, patients will receive pre-visit text message reminders about the flu vaccine, and clinicians will receive a default pended order in the visit encounter in the EHR, along with monthly peer comparison feedback about their flu vaccine completion rate. Patients identified as high risk for noncompletion will be individually randomized to receive an additional bidirectional text message nudge or the standard text messaging
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Oct 2024
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 1, 2024
CompletedFirst Posted
Study publicly available on registry
October 3, 2024
CompletedStudy Start
First participant enrolled
October 21, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 28, 2025
CompletedResults Posted
Study results publicly available
March 30, 2026
CompletedMarch 30, 2026
March 1, 2026
4 months
October 1, 2024
February 3, 2026
March 26, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Proportion of Patients Who Receive the Flu Vaccine at the Visit
The primary outcome is flu vaccination completion during the first eligible primary care visit.
4 days from enrollment, at the eligible visit
Secondary Outcomes (1)
Proportion of Patients Who Receive the Flu Vaccine Within 3 Months After the Visit
3 months
Study Arms (3)
Control
NO INTERVENTIONClinics randomized to the control arm will receive standard of care.
Intervention Arm
EXPERIMENTALClinics randomized to the intervention arm will receive the toolkit of clinician and patient facing nudges. Patient nudges will be pre-visit text message reminders (standard messaging content). Clinician nudges will be monthly peer comparison feedback and default pended orders.
High Risk Intensification Arm
EXPERIMENTALPatients in the intervention clinics identified as high risk for noncompletion of the flu vaccine will be randomized 1:1 to receive the high risk intensification arm or remain in the standard intervention arm. Patients in the high risk intensification arm will receive an additional bidirectional texting component.
Interventions
Patients will be sent text message reminders 3 days and 24 hours prior to their scheduled primary care visit. The messages will inform the patient that a flu shot has been reserved for them at their upcoming visit and encourage the patient to ask their provider about receiving the vaccine.
A default pended order for the flu vaccine will be pended to the patients upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
Each month, clinicians will be sent an email containing what percent of their eligible patients received the flu vaccine and how that compares to other peer clinicians in the intervention
High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component prior to their visit. This intervention will query the patient about common questions or concerns about receiving the flu vaccine. If the patient responds, it will provide additional educational materials based on the patient's specific concern(s).
Eligibility Criteria
You may qualify if:
- All patients must meet the following criteria to be eligible:
- Age ≥ 50 years
- A scheduled new or return (non-urgent/sick) primary care appointment at one of the study practices at Lancaster General Health
- Have not received their annual flu vaccine during the active intervention period (September- February)
- Eligible to receive the flu vaccine
- For the patient intensification nudge, at least one of the following criteria must be met to be considered high risk and randomized to receive the intensification nudge:
- Age ≥ 70 years
- Living in a lower income community (lowest quartile, zip-code based)
- Did not receive a flu vaccine in the previous calendar year
- Self-identifies as Non-Hispanic Black
- Clinicians must meet the following criteria to be eligible to receive peer comparison feedback:
- Practicing physician (MD, DO) or advanced practice provider (NP, PA) with the exception of residents and fellows
- Have a minimum patient panel of at least 50 patients, and
- Practicing at a clinical site randomized to receive the clinic-level nudge interventions.
You may not qualify if:
- Patients will be excluded from the study if they:
- Have a documented allergy to flu vaccine
- Have opted out of research according to individual site guidelines and policies
- Have no phone number (home or mobile) listed in their chart
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Pennsylvanialead
- National Institute on Aging (NIA)collaborator
Study Sites (1)
Lancaster General Health
Lancaster, Pennsylvania, 17602, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Dr. Shivan Mehta
- Organization
- University of Pennsylvania
Study Officials
- PRINCIPAL INVESTIGATOR
Shivan Mehta, MD, MBA, MSHP
University of Pennsylvania
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Chief Innovation Officer, Associate Professor of Medicine
Study Record Dates
First Submitted
October 1, 2024
First Posted
October 3, 2024
Study Start
October 21, 2024
Primary Completion
February 28, 2025
Study Completion
May 28, 2025
Last Updated
March 30, 2026
Results First Posted
March 30, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, ANALYTIC CODE
- Time Frame
- Within one year of trial completion.
We will share our analytical code(s).